Abbott Laboratories (ABT) on Monday announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries.
The company said patients in the first phase of the ABSORB trial experienced no stent thrombosis out to three years and no new major adverse cardiac events between six months and three years.
To build upon the promising results of the ABSORB trial, Abbott said, it is initiating a large-scale trial called ABSORB EXTEND, which will enroll about 1,000 patients from up to 100 centers in Europe, Asia Pacific, Canada and Latin America.
ABSORB EXTEND is a single-arm study designed to further evaluate the performance of Abbott's proprietary fully bioabsorbable stent technology. The study will enroll patients with more complex coronary artery disease and is slated to begin enrolling before the end of the year.
Abbott also announced that patient enrollment is complete for the second phase of the ABSORB trial.
For comments and feedback: editorial@rttnews.com